hotspot -WSS

hotspot

author：fashion 2025-10-01 12:35:37 - browse：78424

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

focus

WSS

ACA's risk program benefits Blue Cross Blue Shield insurers

EpiPen alternative approval delay highlights citizen petition issue

CDC's new outbreak response network to include Northeastern

Swim instructor mom warns parents not to buy blue swimsuits for kids

What Congress can do to address the rural doctor shortage

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

knowledge

hotspot

Gilead needs Arcellx more than ever

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Duchenne breakthrough therapy leaves behind pioneering families

Swim instructor mom warns parents not to buy blue swimsuits for kids

Dobbs anniversary: the lost opportunity of abortion as health care

ACA's risk program benefits Blue Cross Blue Shield insurers

Tori Bowie and the unacceptable rates of Black maternal death

Second xenotransplant done with gene

Apple is now the first public company to be valued at $3 trillion

Presidential fundraising highlights so far: Trump brings in more than DeSantis

focus

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

Biden declares emergency in flood

Eisai exec who led development of Alzheimer’s drug to retire

Lasker Awards 2023: Winners in biomedical research

Second xenotransplant done with gene

Second xenotransplant done with gene

explore

focus

hotspot

leisure time